8 weeks, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of YJP-14 on inhibition of blood circulatio
Not Applicable
Recruiting
- Conditions
- Not Applicable
- Registration Number
- KCT0003096
- Lead Sponsor
- Yang Ji Chemical
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1) Male and female subjects over 35 years and under 75 years of age inclusive
2) platelet aggregability(Collagen, Adenosine Diphosphate) over 55%
3) Subjects who agree the particpation in the trial and submit informed and consent before the beginning of the trial.
Exclusion Criteria
1) Subjects with systolicBP = 160 mmHg or diastolicBP = 100 mmHg and also taking a beta blocker or a hydragogue.
2) Woman who are pregnant of lactating or planning to pregnant
3) Subjects which in the opinion investigator could affect preclude evluation of response
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method platelet aggregability(Collagen, Adenosine Diphosphate, Thrombin Receptor)
- Secondary Outcome Measures
Name Time Method Thromboxane B2;Serotonin;C-Reactive Protein;Total cholesterol;Triglyceride;HDL-cholesterol;LDL-cholesterol